Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells

Neoplasia

Volumn 11, Issue 9, 2009, Pages 835-845

  Chen, Ya Wen ^a   Boyartchuk, Victor ^a   Lewis, Brian C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; HETERODIMER; INSULIN RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL INVASION; CELL MIGRATION; CIRCULATION; CONTROLLED STUDY; LIVER CELL CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; IMMUNOBLOTTING; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PHENOTYPE; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 69249096951     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09476     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108.
2. Breuhahn K, Longerich T, and Schirmacher P (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25, 3787-3800.
3. Lund P, Schubert D, Niketeghad F, and Schirmacher P (2004). Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 206, 85-96.
4. Samani AA, Yakar S, LeRoith D, and Brodt P (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28, 20-47.
5. Riedemann J and Macaulay VM (2006). IGF1R signalling and its inhibition. Endocr Relat Cancer 13 (Suppl 1), S33-S43.
6. LeRoith D and Roberts CT Jr (2003). The insulin-like growth factor system and cancer. Cancer Lett 195, 127-137.
7. Oka Y, Rozek LM, and Czech MP (1985). Direct demonstration of rapid insulin-like growth factor II receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. J Biol Chem 260, 9435-9442.
8. Reeve AE, Eccles MR, Wilkins RJ, Bell GI, and Millow LJ (1985). Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature 317, 258-260.
9. Lambert S, Collette J, Gillis J, Franchimont P, Desaive C, and Gol-Winkler R (1991). Tumor IGF-II content in a patient with a colon adenocarcinoma correlates with abnormal expression of the gene. Int J Cancer 48, 826-830.
10. Baghdiguian S, Verrier B, Gerard C, and Fantini J (1992). Insulin like growth factor I is an autocrine regulator of human colon cancer cell differentiation and growth. Cancer Lett 62, 23-33.
11. Favoni RE, de Cupis A, Ravera F, Cantoni C, Pirani P, Ardizzoni A, Noonan D, and Biassoni R (1994). Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer 56, 858-866.
12. Toropainen E, Lipponen P, and Syrjanen K (1995). Expression of insulin-like growth factor I (IGF-I) in female breast cancer as related to established prognostic factors and long-term prognosis. Eur J Cancer 31A, 1443-1448.
13. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, and Pollak M (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566.
14. Kiess W, Yang Y, Kessler U, and Hoeflich A (1994). Insulin-like growth factor II (IGF-II) and the IGF-II/mannose-6-phosphate receptor: the myth continues. Horm Res 41 (Suppl 2), 66-73.
15. Li X, Cui H, Sandstedt B, Nordlinder H, Larsson E, and Ekstrom TJ (1996). Expression levels of the insulin-like growth factor-II gene (IGF2) in the human liver: developmental relationships of the four promoters. J Endocrinol 149, 117-124.
16. Christofori G, Naik P, and Hanahan D (1994). A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369, 414-418.
17. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, Ullrich A, and Brechot C (1988). Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 48, 6844-6849.
18. Schirmacher P, Held WA, Yang D, Chisari FV, Rustum Y, and Rogler CE (1992). Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 52, 2549-2556.
19. Yang DY and Rogler CE (1991). Analysis of insulin-like growth factor II (IGF-II) expression in neoplastic nodules and hepatocellular carcinomas of woodchucks utilizing in situ hybridization and immunocytochemistry. Carcinogenesis 12, 1893-1901.
20. Liu P, Terradillos O, Renard CA, Feldmann G, Buendia MA, and Bernuau D (1997). Hepatocarcinogenesis in woodchuck hepatitis virus/c-myc mice: sustained cell proliferation and biphasic activation of insulin-like growth factor II. Hepatology 25, 874-883.
21. Lewis BC, Klimstra DS, Socci ND, Xu S, Koutcher JA, and Varmus HE (2005). The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 25, 1228-1237.
22. Li X, Nong Z, Ekstrom C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes HP, Ekstrom TJ, et al. (1997). Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 57, 2048-2054.
23. Sohda T, Yun K, Iwata K, Soejima H, and Okumura M (1996). Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 75, 307-311.
24. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, et al. (2002). Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176, 149-158.
25. Piao Z, Choi Y, Park C, Lee WJ, Park JH, and Kim H (1997). Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma. Cancer Lett 120, 39-43.
26. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, and Jirtle RL (1995). Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10, 1725-1729.
27. De Souza AT, Hankins GR, Washington MK, Orton TC, and Jirtle RL (1995). M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11, 447-449.
28. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K, and Hintz R (1994). Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 269, 13779-13784.
29. Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, and Meng XY (2005). Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 11, 4655-4660.
30. Chen YW, Paliwal S, Draheim K, Grossman SR, and Lewis BC (2008). p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res 68, 476-482.
31. Chen YW, Klimstra DS, Mongeau ME, Tatem JL, Boyartchuk V, and Lewis BC (2007). Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res 67, 7589-7596.
32. Parrizas M, Gazit A, Levitzki A, Wertheimer E, and LeRoith D (1997). Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138, 1427-1433.
33. Dearth RK, Cui X, Kim HJ, Hadsell DL, and Lee AV (2007). Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 6, 705-713.
34. Ma Z, Gibson SL, Byrne MA, Zhang J, White MF, and Shaw LM (2006). Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol 26, 9338-9351.
35. Nagle JA, Ma Z, Byrne MA, White MF, and Shaw LM (2004). Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 24, 9726-9735.
36. Deryugina EI and Quigley JP (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25, 9-34.
37. Vernon AE and LaBonne C (2004). Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol 14, R719-R721.
38. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, and Burfeind P (2004). Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol 202, 50-59.
39. Long L, Navab R, and Brodt P (1998). Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res 58, 3243-3247.
40. Yoon A and Hurta RA (2001). Insulin like growth factor-1 selectively regulates the expression of matrix metalloproteinase-2 in malignant H-ras transformed cells. Mol Cell Biochem 223, 1-6.
41. Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P, Breuhahn K, et al. (2008). Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 25, 3787-3800.
42. Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R, Baserga R, and Barrett JC (1998). A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 58, 3353-3361.
43. Sachdev D, Hartell JS, Lee AV, Zhang X, and Yee D (2004). A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279, 5017-5024.
44. Arden KC (2007). FoxOs in tumor suppression and stem cell maintenance. Cell 128, 235-237.